Hepatology:2D-MRE诊断NAFLD进展期肝纤维化

2014-12-10 MedSci MedSci原创

Fig1. Diagnostic accuracy of MRE for advanced fibrosis. AUROC for the detection of advanced fibrosis in patients with biopsy-proven NAFLD is shown, and a two-tailed P value is provided. TPR, true po

Fig1. Diagnostic accuracy of MRE for advanced fibrosis. AUROC for the detection of advanced fibrosis in patients with biopsy-proven NAFLD is shown, and a two-tailed P value is provided. TPR, true positive rate; FPR, false-positive rate.


 Fig3. MRE stiffness maps of 5 patients with NAFLD and different stages of liver fibrosis. Shown are MRE stiffness maps in 5 patients with NAFLD. These maps depict the spatial distribution of stiffness (in kPa) within the liver (outlined in white). As shown in the color lookup table at the right, the stiffness values range from near zero (dark purple) to 8 kPa (red). The histology-determined liver fibrosis stage is shown at the top of each stiffness map, and the MRE-determined mean liver stiffness is shown at the bottom of each image. Notice that the stiffness values are greater in patients with more-advanced fibrosis.

目的:回顾性研究已经证实了一种新型的评估肝脏硬度的磁共振成像技术-二维磁共振成像(two-dimensional magnetic resonance elastography,2D-MRE)与非酒精性肝硬化(nonalcoholic fatty liver disease, NAFLD)导致的进展期肝纤维化密切相关。但仍需大量的2D-MRE诊断NAFLD准确性的前瞻性研究数据。本研究的目是前瞻性评估无创2D-MRE诊断3、4级NAFLD的准确性。

方法:本前瞻性研究采用横断面调查方法分析了117例(女性 56%)活检证实为NAFLD患者,患者检查项目包括病史、体格检查、肝穿刺活检(评估采用非酒精性脂肪肝炎临床研究组织学评分系统)、2D-MRE。随访时间从2011年到2013年。放射科医生和病理科医生分别采用盲法检测患者的影像及病理学数据。用接受者操作特征曲线(ROC曲线)评估2D-MRE对 NAFLD的诊断价值。

结果:患者平均年龄50.1±13.4岁,BMI指数32.4±5kg/m2,肝穿刺活检与2D-MRE间隔的中位时间为45天。0、1、2、3、4级肝纤维化患者人数分别43人、39人、13人、12人、10人。2D-MRE区别3-4级肝纤维化与0-2级肝纤维化的ROC曲线下面积为0.924 (P < 0.0001).阈值大于3.6KPa的灵敏性为0.86(95%的可信区间0.65-0.97),特异性为0.91(95%的可信区间0.83-0.96),阳性预测值为0.68(95%的可信区间0.48-0.84),阴性预测值为0.97(95%的可信区间0.91-0.99).

结论:2D-MRE可以准确诊断进展期肝纤维化,可以作为NAFLD进展期肝纤维化无创检查的一种方法。

原始出处

Loomba R1, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, Valasek M, Lin G, Brenner D, Gamst A, Ehman R, Sirlin C.Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study.Hepatology. 2014 Dec

本文是MedSci原创编译整理,欢迎转载!转载请注明来源并附原文链接。谢谢!


您还可以这样阅读,更多资讯,请关注MedSci微信
  


 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1649495, encodeId=56c0164949531, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Sun May 10 18:24:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814013, encodeId=031b1814013ff, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Aug 27 23:24:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083878, encodeId=317e20838e81e, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Wed Oct 07 19:24:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808126, encodeId=85141808126f1, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Oct 23 12:24:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426597, encodeId=1005142659e6a, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 12 08:24:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]
    2015-05-10 freve
  2. [GetPortalCommentsPageByObjectIdResponse(id=1649495, encodeId=56c0164949531, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Sun May 10 18:24:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814013, encodeId=031b1814013ff, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Aug 27 23:24:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083878, encodeId=317e20838e81e, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Wed Oct 07 19:24:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808126, encodeId=85141808126f1, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Oct 23 12:24:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426597, encodeId=1005142659e6a, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 12 08:24:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1649495, encodeId=56c0164949531, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Sun May 10 18:24:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814013, encodeId=031b1814013ff, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Aug 27 23:24:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083878, encodeId=317e20838e81e, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Wed Oct 07 19:24:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808126, encodeId=85141808126f1, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Oct 23 12:24:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426597, encodeId=1005142659e6a, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 12 08:24:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]
    2015-10-07 lvygwyt2781
  4. [GetPortalCommentsPageByObjectIdResponse(id=1649495, encodeId=56c0164949531, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Sun May 10 18:24:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814013, encodeId=031b1814013ff, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Aug 27 23:24:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083878, encodeId=317e20838e81e, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Wed Oct 07 19:24:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808126, encodeId=85141808126f1, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Oct 23 12:24:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426597, encodeId=1005142659e6a, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 12 08:24:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1649495, encodeId=56c0164949531, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Sun May 10 18:24:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814013, encodeId=031b1814013ff, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Aug 27 23:24:00 CST 2015, time=2015-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083878, encodeId=317e20838e81e, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Wed Oct 07 19:24:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808126, encodeId=85141808126f1, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Oct 23 12:24:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426597, encodeId=1005142659e6a, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Dec 12 08:24:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]
    2014-12-12 gwc384

相关资讯

APASL 2014:中国植物药—肝纤维化治疗的新方法

目前全球有数以百万计的患者正在使用中药进行治疗,而实际上几乎没有关于评估中药治疗是否真正有效的随机、双盲、安慰剂对照、多中心的试验研究。 John Vierling教授于3月14日在APASL 2014上就中药制剂“扶正化瘀片”对减少大多数患者肝脏纤维化程度的能力所进行的II期临床试验进行汇报,研究发现该药能改善患者的恢复,减缓肝脏纤维化进展。 扶正化瘀片是一种从丹参、发酵虫草菌粉、桃仁、松花

APT:ALT正常的慢乙肝患者肝纤维化比例仍较高

慢性乙型肝炎(CHB)可以导致肝硬化,肝癌和过早死亡。升高的丙氨酸转氨酶(ALT)水平≥标准上限(ULN)的上限是评估是否进行抗病毒治疗的主要决定因素,但是,单独ALT水平可能不是预测肝纤维化。但慢乙肝患者的ALT正常时,患者肝脏的纤维化情况究竟如何目前未有定论。来自斯坦福大学的研究人员对此进行了系统回顾与荟萃分析。 研究表明ALT ≤ 40 IU / L的慢乙肝患者,约五分之一可能有显

Hepatology:HIV/HCV共感染患者的肝纤维化进展迅速

人免疫缺陷病毒HIV/丙肝病毒HCV共感染与进展性肝病相关。然而,进展的比例是多变的,并且在区分病人的HCV疾病处于稳定或进展状态上的能力十分有限。HIV/HCV共感染患者肝纤维化进展的速率和危险因素尚不明确。 来自美国约翰霍普金斯医院的Monica A. Konerman等人对此进行研究,结果发现HCV/HIV共感染患者的肝纤维化进展迅速。该研究结果发表在2014年3月的Hepatology上

PNAS:常见肥皂成分可能致癌

科学家们发现,个人卫生产品中的常用抗菌成分——三氯生,会小鼠患上肝纤维化和癌症。 三氯生(Triclosan)是肥皂、洗发水、沐浴露、牙膏等许多日化产品常用的抗菌成分,用途非常广泛。加州大学医学院的研究团队发现,长期接触这种化合物可能会导致严重的后果,这项研究发表在十一月十七日的美国国家科学院院刊PNAS杂志上。研究显示,三氯生会在实验室小鼠中引发肝纤维化和癌症,而且这个效果所涉及的分子

J Clin Pathol:肝纤维化指数可以有效预测肝癌的发生

肝细胞癌(HCC)是引起全球癌症相关性死亡其中一个重要的原因。由于>80%的肝细胞癌都在肝纤维化或肝硬化的基础上发生,似乎肝脏的慢性损伤-修复过程是导致肝细胞癌产生的一个重要因素。伴有严重纤维化的肝癌病人存活期总体来说低于那些没有肝纤维化的病人。血清学标记物,包括AFP和异常甲基化DNA,另外还有影像学技术,都被用作HCC的早期检测。通过血清AFP检测HCC的方法受到其低灵敏度的限制,而影像学技术